Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASE1 | P07998 | 1/20 | 0.59 |
| ▸ | TK1 | P04183 | 4/20 | 0.44 |
| ▸ | TK2 | O00142 | 3/20 | 0.44 |
| ▸ | ALB | P02768 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6572381 | 1.00 | RNASE1 (0.59) | RNASE1TK1TK2ALBPKM | |
| SCHEMBL7643615 | 0.93 | RNASE1 (0.51) | RNASE1TK1 | |
| SCHEMBL7644968 | 0.92 | RNASE1 (0.59) | RNASE1TK1TK2 | |
| SCHEMBL8719327 | 0.92 | RNASE1 (0.59) | RNASE1TK1TK2 | |
| SCHEMBL8722179 | 0.91 | RNASE1 (0.58) | RNASE1TK1TK2ALBPKM | |
| SCHEMBL7644538 | 0.91 | RNASE1 (0.58) | RNASE1TK1TK2ALBPKM | |
| SCHEMBL6834245 | 0.90 | RNASE1 (0.53) | RNASE1TK1TK2ALBPKM | |
| SCHEMBL6834409 | 0.90 | RNASE1 (0.53) | RNASE1TK1TK2ALBPKM | |
| SCHEMBL6834411 | 0.90 | RNASE1 (0.53) | RNASE1TK1TK2ALBPKM | |
| SCHEMBL7053656 | 0.90 | RNASE1 (0.53) | RNASE1TK1TK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040203036-A1 | Multimer polynucleotide synthesis | CHEMOGENIX GMBH (DE) | 2004-10-14 | — | — | US | disclosed |
| US-6756492-B1 | Nucleoside derivatives with photo-unstable protective groups | DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUND DES OFFENTLICHEN RECHTS (DE) | 2004-06-29 | — | — | US | disclosed |
| EP-1409505-A1 | MULTIMER POLYNUCLEOTIDE SYNTHESIS | Chemogenix GmbH (DE) | 2004-04-21 | — | — | EP | disclosed |
| WO-2003006476-A1 | MULTIMER POLYNUCLEOTIDE SYNTHESIS | CHEMOGENIX GMBH (DE) | 2003-01-23 | — | — | WO | disclosed |
| US-5763599-A | FOR LIGHT-CONTROLLED SYNTHESIS OF OLIGONUCLEOTIDES ON DNA CHIP | Pfleiderer, Wolfgang (DE) | 1998-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040203036-A1 | Multimer polynucleotide synthesis | NT5C3B, PCNA, POLL | RNASE1 205/4885TK1 176/4885TK2 265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.